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Cystic Fibrosis (CF) is a multisystem disease predominantly affecting the airways and predisposing pa-
tients to recurrent infections with various multidrug resistant organisms. Mycobacterium tuberculosis
(MTB) infection is rarely seen, but considered a potential pathogen in CF patients. We report a 26 year old
pregnant CF patient on Ivacaftor who was admitted with symptoms suggestive of tuberculosis. Three
years prior to the current admission, she had completed four drug anti- MTB therapy for pulmonary
tuberculosis and was considered cured as her sputum cultures after six months of treatment were
negative. Genotype analysis revealed the current MTB strain to be different from the strain causing the
previous infection. After receiving ﬁrst line anti-tuberculous regimen for nine months, the patient's
condition markedly improved culminating in an uneventful pregnancy and delivery. To our knowledge,
this is the only reported case of reinfection tuberculosis in a CF patient.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cystic Fibrosis (CF) is an autosomal recessive disorder caused by
a mutation in Cystic Fibrosis Transmembrane Conductance Regu-
lator [CFTR] gene, a complex chloride channel and regulatory pro-
tein. Typically, CF leads to multisystem involvement,
predominantly affecting the airways with inability to clear viscous
secretions, mucus plugging, and intense inﬂammation due to lack
of the regulatory protein. This predisposes them to recurrent in-
fections with various multidrug resistant organisms, leading to
bronchiectasis and ﬁbrotic lung disease. Several studies have
shown that Non Tuberculous Mycobacteria (NTM) occur in CF pa-
tients, but Mycobacterium Tuberculosis (MTB) infection is rarely
seen in these patients and only a few cases have been reported in
the literature [1e4]. We report a CF patient with DG551Dmutation,
on Ivacaftor, previously treated with a full course of Anti Tuber-
culous Therapy (ATT), whowas reinfected with a new strain of MTB
three years later.ealth, USA.
il).
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A 26-year-old Caucasian female at 18 weeks of gestation and a
history of CF with D G551D mutation on Ivacaftor, a CF Trans-
membrane Conductance Regulator (CFTR) potentiator, was found to
have recurrent admissions to the hospital with exacerbations of her
pulmonary symptoms of cough and purulent sputum production,
dyspnea on exertion, pleuritic chest pain and small amount of he-
moptysis. The vital signs were stable except for a low grade fever of
99.5 F. Blood cultures were negative, but she was known to harbor
multi-drug resistant Pseudomonas aeruginosa, Methicillin Resistant
Staphylococcus aureus (MRSA), Achromobacter species and Asper-
gillus fumigatus in her bronchial airways, and had been treated
multiple times in the past for these infections. She was not on any
immunosuppressive drugs and did not have any other medical
problems. Her chest radiograph revealed bilateral diffuse retic-
ulonodular opacities which had remained stable over the past two
years (Fig. 1). She had been treated for pulmonary tuberculosis
three years ago, with a regimen that included Isoniazid (INH),
Rifampin (RIF), Ethambutol (EMB) and Pyrazinamide (PZA) in the
intensive phase for two months, followed by four months of INH
and RIF in the continuation phase. Her sputum cultures after
completion of therapywere negative for MTB. Two sputum cultures
during the current admission revealed MTB, but on genotype
analysis, it was found to be a different MTB strain from the one shender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest Radiograph with bilateral reticulonodular changes and chronic right
upper lobe paratracheal consolidation during this admission.
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tion of antitubercular treatment. Drug susceptibility testing
showed sensitivity to all ﬁrst-line drugs (INH, RIF, EMB, PZA). Due
to her pregnancy, she was given a three drug regimen of INH, RIF
and EMB for nine months. Her repeat sputum cultures were
negative for MTB six weeks after therapy was initiated. She toler-
ated the regimen well with an improvement in her symptoms and
delivered a full term male fetus without any complications. The
patient was lost to follow-up after completion of therapy and all
efforts to contact her thereafter were unsuccessful.
3. Discussion
NTM infections are seen in approximately 7e13% of CF patients
[4]. In vitro studies have shown that NTM invades respiratory
epithelium with a protein that attaches to ﬁbronectin within the
exposed extracellular matrix on the damaged mucosal surfaces,
unlike MTB that adheres to intact mucosa [5]. However, despite
having multiple risk factors such as malnutrition, diabetes mellitus,
steroid use and chronic lung disease, MTB is rarely seen among CF
patients [4,6]. The etiology for this rarity is not well deﬁned, but
several pathways have been suggested that point to a genetic
component of the disease or a defect in enzyme activity [7,8]. It was
reported in one study that carriers of this recessive gene are
resistant to Mycobacterium tuberculosis infection, which is attrib-
uted to the production of excessive amounts of hyaluronic acid in
these individuals [8]. Another possible explanation is the dimin-
ished activity of arylsulfatase, a lysosomal enzyme, in CF patients
compared to normal population [9]. Reduction in the activity of this
enzyme by decreasing the availability of sulfate may have evolved
as a mechanism to confer protection against M. tuberculosis pro-
liferation in CF patients [9,10]. Mutation in the G551D gene in CF
patients is caused by the substitution of the amino acid glycine by
aspartate at position 551 in the nucleotide binding domain-1 of the
CFTR gene. Ivacaftor, a CFTR potentiator, speciﬁcally targets the
G551D gating mutation by improving the chloride transport and
increasing the channel opening probability through a non-
conventional ATP independent mechanism [11]. Targeted therapy
with Ivacaftor normalizes the respiratory mucosa making them
more susceptible to MTB infections than NTM. Our patient was not
on this therapy when she had her initial MTB infection, but was on
it during the current admission. Literature review reveals no cases
of MTB infections that have been reported with the use of this
therapy.TB genotyping is a laboratory-based approach used to examine
the genetic material of M. tuberculosis. Population-based genotyp-
ing using two Polymerase Chain Reaction based methods, spoli-
gotyping andMycobacterial Interspersed Repetitive Units, has been
available in USA since 2004. Speciﬁc sections of the genetic content
help in distinguishing between dissimilar strains of M. tuberculosis
based on the distinct genetic patterns formed [12]. The isolate from
the second episode was genotype G07350, which was in a cluster
with a pleural TB case from another county in Arkansas reported in
May of 2010. Given that she completed treatment in August 2011
and we diagnosed her with a second episode of TB in March 2013,
her most likely source of re-exposure was a TB case outside
Arkansas. In the time frame above, four TB cases of the same ge-
notype were reported from Tennessee, three from Mississippi and
one from Oklahoma. However, there were no other TB cases
nationwide. Thus, this cluster is limited to contiguous states, but we
could not ﬁnd any epidemiological links between these cases. With
the help of genotype analysis of the specimen, we were able to
identify that our patient was infected with different strains of MTB
on the two occasions, ﬁrst with G08667 and thenwith G07350. This
conﬁrmed that the current MTB was a reinfection and not a relapse
of the previous infection. Laboratory cross-contamination is
considered unlikely since two separate sputum cultures grew MTB
at different points of time.
The diagnosis of M. tuberculosis is established by a combination
of Interferon Gamma Release Assays (IGRA), Tuberculin Skin Test
(TST), Acid Fast Bacillus (AFB) sputum smear and culture exami-
nation, and more recently the GeneXpert MTB/RIF assay (Cepheid
Inc.) [13]. The standard regimen for MTB is an initial two month
intensive phase followed by a four month continuation phase [14].
The duration of therapy is prolonged by factors like cavitation on
initial chest X-ray and positive cultures on completion of two
months of the initial phase of therapy. It is recommended that
molecular drug susceptibility testing of the initial MTB isolate be
conducted for all patients and should be repeated at threemonths if
no signiﬁcant clinical improvement is observed [15]. Failure to
complete MTB therapy is associated with high recurrence rate and
drug resistance, thus ensuring medication compliance of all pa-
tients with MTB infection is essential [7].
The treatment of MTB in CF patients follows general guidelines
and the standard therapeutic regimen of six months duration.
Recurrent MTB requires another cycle of standard regimen, which
in some cases like our patient, needs an extended length of therapy.
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